N-[(2S)-4-methyl-1-oxo-1-[(3-oxo-1-pyridin-2-ylsulfonylazocan-4-yl)amino]pentan-2-yl]-1-benzothiophene-2-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[(2S)-4-methyl-1-oxo-1-[(3-oxo-1-pyridin-2-ylsulfonylazocan-4-yl)amino]pentan-2-yl]-1-benzothiophene-2-carboxamide
• 化学式: C₂₇H₃₂N₄O₅S₂
• 分子量: 556.7
• InChiKey: DBLKWEUSHAUZKU-LBAQZLPGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  162
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• EP1140897A4
  申请人：——

  公开号：EP1140897A4

  公开（公告）日：2002-04-03
• PROTEASE INHIBITORS
  申请人：SmithKline Beecham Corporation

  公开号：EP1140897A1

  公开（公告）日：2001-10-10
• [EN] PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTEASES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2000039115A1

  公开（公告）日：2000-07-06

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods of treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis, gingival disease including gingivitis and periodontitis; arthritis, more specifically osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia or malignancy and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.